Capricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics.
FDA's CTGTAC voted 9-3 against Capricor's deramiocel on July 30, 2026. The science wasn't the problem. The statistical methodology...
FDA's CTGTAC voted 9-3 against Capricor's deramiocel on July 30, 2026. The science wasn't the problem. The statistical methodology...
FDA's July 27 briefing document for Deramiocel (BLA 125842) contradicts Capricor's Phase 3 efficacy claims ahead of tomorrow's AdCom...
CMS's proposed 2027 fee schedule would ban Medicare payments for third-party RPM vendors after OIG flagged $536M in billing...
Elevar Therapeutics received its third FDA CRL in two years for rivoceranib plus camrelizumab in liver cancer, each citing...
FDA's June 2026 warning letter to Genzyme Ireland over Altuviiio manufacturing exposes how post-approval CGMP oversight collapses at the...
FDA issued Sobi a CRL for NASP on June 26, 2026, citing third-party manufacturing failures. Here's the operational breakdown...
FDA's April 2026 warning letter to Zoll Medical exposes quality control and MDR violations at a cardiopulmonary device maker...
ADC Therapeutics' LOTIS-5 trial shows 13.2% fatal events vs. 4.6% in controls—a 3:1 death imbalance that exposes accelerated approval's...
Eli Lilly gave 1,000+ hospitals five days to submit claims data or lose 340B discounts—exposing how pharma giants shift...
AstraZeneca's Etcamah won EMA approval weeks after FDA adcom rejection—exposing a regulatory split that demands answers on endpoint standards...